FY20 ends on a high; cost base to increase in FY21
24/02/21 -"FY20 sales and operating profit targets were exceeded, led by higher Darzalex royalties and lower R&D costs. Given its convenience dosing, Darzalex should hit the $5bn sales mark in FY21 (vs. ..."
Pages
54
Language
English
Published on
24/02/21
You may also be interested by these reports :
24/03/21
Roche has provided a re-assuring update for its Diagnostics division. Besides leveraging the COVID-19 testing opportunity, the group is ...
19/03/21
Faes’ FY20 reported earnings benefited from higher milestone income and lower operating costs (reduction in commercial, travelling, and marketing ...
16/03/21
Concerns surrounding the EU’s COVID-19 vaccination campaign refuse to die down. With AstraZeneca now reporting a safety scare – after already ...
15/03/21
Merck KGaA (Add, Germany) belongs to those groups that enjoy the benefit of a long-term view thanks to absolute family control but are nominally ...